Welcome to our dedicated page for Innocan Pharma news (Ticker: INNPF), a resource for investors and traders seeking the latest updates and insights on Innocan Pharma stock.
Innocan Pharma Corporation (INNPF) appears in news coverage as a pharmaceutical technology company active in both pharmaceuticals and wellness. Company announcements describe a focus on a CBD-loaded liposome drug delivery platform for non-opioid pain management, as well as the development and marketing of self-care and beauty products through a wellness segment.
News items about Innocan often highlight developments related to its liposomal CBD drug products and chronic pain management initiatives. Coverage may also include updates on regulatory milestones, such as references to U.S. Food and Drug Administration pathways for human health applications and Investigational New Animal Drug numbers for animal health applications, as reported by the company.
In addition, Innocan’s news flow includes capital markets and listing developments. The company has announced that it anticipates listing on the NYSE American stock exchange, in connection with a concurrent offering of its securities, while its shares trade on the Canadian Securities Exchange and the OTCQB. These items are presented by the company as forward-looking and subject to regulatory and market conditions.
Readers following INNPF news can expect updates on conference presentations, regulatory interactions, anticipated exchange listings, and business activities in both the pharmaceutical and wellness segments. This page aggregates such company-issued news and related coverage so that investors and observers can review Innocan’s publicly reported developments in one place.
Innocan Pharma (symbol: INNPD) announced it anticipates listing on NYSE American on or around January 7, 2026, subject to listing application approval and continued compliance with exchange rules. The company said its common shares are expected to continue trading on OTCQB until the close of market on or about January 6, 2026, after which OTCQB trading will terminate upon NYSE effectiveness. Innocan will remain listed on the Canadian Securities Exchange under INNO. Concurrently, the company is conducting a securities offering subject to market conditions and regulatory approval; additional offering details will be disclosed in SEC and SEDAR+ filings.
Innocan Pharma (CSE: INNO, FSE: IP4, OTCQB: INNPF) has announced its participation in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. This event brings together institutional investors, corporate clients, and industry professionals to showcase innovations and financial strategies.
The company will highlight its recent regulatory achievements, including FDA approval for a 505(2)(b) abbreviated pathway for human health applications, a sponsor fee waiver, and an Investigational New Animal Drug number (INAD) for animal health applications from the FDA Center for Veterinary Medicine.
Iris Bincovich, CEO of Innocan Pharma, will present at 2PM ET in the Lotus Suite West. The management team will also conduct one-on-one investor meetings throughout the day. Interested investors can register to attend and schedule meetings online.
FAQ
What is the current stock price of Innocan Pharma (INNPF)?
What is the market cap of Innocan Pharma (INNPF)?
